The first treatment since the 1950s has been approved by the US Food and Drug Administration for the treatment of Tardive Dykinesia.
Ingrezza was approved in 2017. Another medication is expecting to be approved by the FDA in the summer of 2017.
Approximately one-quarter of patients with schizophrenia are affected by tardive dyskinesia (TD), a serious, and potentially disabling, movement disorder. Patients treated with other dopamine blocking agents (DBAs), such as metoclopramide, can also be affected.
Below is the link to an educational supplement published by Psychiatric Times, an American Psychiatric Association journal
This educational supplement briefly reviews key recent articles that discuss:
• Screening instruments and guidelines
• Genetic and non-genetic risk factors
• Leading hypotheses for the epidemiology of TD
• Available treatment options and emerging therapies